Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 4/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL331007 | 0.80 | TSHR (0.57) | CES2CES1TSHRFNTAFNTB | |
| SCHEMBL23979232 | 0.79 | CA2 (0.34) | EGFRERBB2CA2CYP1A2MAPT | |
| SCHEMBL13197240 | 0.78 | POLB (0.45) | CES2CES1TSHRCA2CYP1A2 | |
| SCHEMBL2625190 | 0.78 | LMNA (0.62) | TSHRCYP2D6CYP1A2MEN1KMT2A | |
| SCHEMBL15682633 | 0.76 | ENPP2 (0.45) | — | |
| SCHEMBL10137814 | 0.75 | CA2 (0.56) | TSHRCA2MEN1KMT2AAKR1B1 | |
| SCHEMBL23979233 | 0.74 | CYP1A2 (0.42) | CES2CES1TSHRFNTAFNTB | |
| Phosphonic Acid SCHEMBL11615478 | 0.74 | TSHR (0.50) | CES2CES1TSHRFNTAFNTB | |
| SCHEMBL14462168 | 0.73 | MAPT (0.48) | TSHRCYP2D6CYP1A2MEN1KMT2A | |
| SCHEMBL8234154 | 0.73 | HTT (0.54) | CYP3A4CYP2D6CYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | ALPHA-9 ONCOLOGY INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| US-20230114807-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2023-04-13 | — | — | US | disclosed |
| US-20220233726-A1 | NOVEL RADIOLABELLED COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-07-28 | — | — | US | disclosed |
| US-20210338851-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338851-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | FOLH1, KLK3, PSMA3 | CES2 4413/4885CES1 3793/4885EGFR 291/4885 |
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | KLK3, FOLH1, TMEM14C | CES2 3454/4885CES1 2323/4885EGFR 563/4885 |
| US-20230114807-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | FOLH1, KLK3, PSMA3 | CES2 4413/4885CES1 3793/4885EGFR 291/4885 |
| US-20220233726-A1 | NOVEL RADIOLABELLED COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER | KLK3, FOLH1, HRH3 | CES2 3390/4885CES1 2006/4885EGFR 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.